J147 for Stroke

(JUMPSTART Trial)

This trial tests whether a new drug, J147, can improve recovery after an ischemic stroke, which occurs when a blood clot blocks blood flow to the brain. Participants will receive J147 by injection (emulsion for injection), and researchers will compare their recovery to those who do not receive the drug. The trial will also assess the drug's safety by monitoring brain scans and blood samples. Ideal candidates are those who have recently experienced a stroke requiring a clot-removal procedure and are not receiving other clot-busting treatments. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people, offering participants a chance to contribute to important advancements in stroke recovery.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that J147 is generally safe for humans. Early studies suggest it maintains a good safety record. For instance, tests found that J147 caused negative effects on cells only at very high doses, exceeding those used in treatment. In studies with healthy individuals, J147 did not exhibit any obvious harmful effects. Additionally, J147 appears to protect the brain by reducing the risk of bleeding after a stroke, potentially lowering the chances of death from a stroke. While these results are promising, ongoing trials must continue to study how well people tolerate J147.¹²³⁴⁵

Unlike standard treatments for stroke, such as clot-busting drugs like tPA or mechanical thrombectomy, J147 is unique because it is derived from an active ingredient initially developed for Alzheimer's disease. Researchers are excited about J147 because it targets cellular aging and inflammation, which are crucial in stroke recovery. This new approach could potentially improve brain repair and recovery after a stroke, offering hope for a more effective treatment. Additionally, J147 is administered as an emulsion for injection, which might enhance its delivery and effectiveness in targeting acute stroke damage.

Research has shown that J147, which participants in this trial may receive, may aid recovery from an ischemic stroke. Studies have found that J147 significantly reduces brain damage when administered soon after a stroke. In animal tests, it decreased the size of the brain injury, suggesting it might help limit stroke damage. J147 also protects brain cells and improves blood flow in the brain, potentially supporting better recovery after a stroke.¹²³⁶⁷